Donoghue Forlines’s Kyntra Bio KYNB Stock Holding History

Donoghue Forlines’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-254	Closed	-$220K	–	215
2021 Q1	$220K	Sell	254 -9	-3%	-$9.58K	0.04%	208
2020 Q4	$244K	Buy	+263	New	+$276K	0.05%	219

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Donoghue Forlines's KYNB Position: Q2 2021 in Review

Donoghue Forlines sold out of Kyntra Bio (KYNB) in Q2 2021, closing a stake of 254 shares — an estimated $220K sold.

Donoghue Forlines first reported a position in KYNB in Q4 2020 and held it in 2 quarters. The position peaked at $244K in Q4 2020. 174 funds tracked by Wall St. Rank hold KYNB as of Q2 2021.

Donoghue Forlines reported no remaining Kyntra Bio position as of Q2 2021 after selling out during the quarter.
Donoghue Forlines sold 254 Kyntra Bio shares in Q2 2021, an estimated $220K.
Donoghue Forlines first reported a position in Kyntra Bio in Q4 2020 and held it in 2 quarters.
Donoghue Forlines's Kyntra Bio position peaked at $244K in Q4 2020.
174 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2021.

Based on Donoghue Forlines's 13F filing for Q2 2021, filed 16 Aug 2021.